A retrospective study to investigates exosomal mRNA expression of PD-L1 and IFN-γ, PD-L1 polymorphisms, tumor mutational load in circulating cell-free DNA as predictive markers of response to nivolumab and pembrolizumab in metastatic NSCLC patients
Latest Information Update: 16 Jun 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 16 Jun 2021 New trial record
- 01 Jun 2021 Results published in the Cancer Immunology Immunotherapy